Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
EBioMedicine
; 93: 104662, 2023 Jul.
Article
de En
| MEDLINE
| ID: mdl-37354600
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Sclérose en plaques chronique progressive
/
Sclérose en plaques récurrente-rémittente
/
Sclérose en plaques
Type d'étude:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Humans
Langue:
En
Journal:
EBioMedicine
Année:
2023
Type de document:
Article